Scientists move closer to developing ‘game-changing’ test to diagnose Parkinson’s

Results published today show it's possible to identify Parkinson’s based on compounds found on the surface of skin. The findings offer hope that a pioneering new test could be developed to diagnose the degenerative condition through a simple and painless skin swab.

Scientists at The University of Manchester have developed a technique which works by analysing compounds found in sebum, the oily substance that coats and protects the skin, and identifying changes in people with Parkinson’s Disease. Sebum is rich in lipid-like molecules and is 1 of the lesser studied biological fluids in the diagnosis of the condition. People with Parkinson's may produce more sebum than normal, a condition known as seborrhoea.

The research has been funded by charities Parkinson’s UK and the Michael J. Fox Foundation, as well as The University of Manchester Innovation Factory. The work was originally funded following an observation by Joy Milne, whose husband was diagnosed with Parkinson’s at the age of 45.

Working with Dr Tilo Kunath at the University of Edinburgh, Joy demonstrated an incredible ability to distinguish a distinctive Parkinson’s odour in individuals using her sense of smell, even before symptoms emerge in those affected.

The team, led by Professor Perdita Barran, The University of Manchester, and the clinical lead Professor Monty Silverdale at Salford Royal Foundation Trust, recruited 500 people with and without Parkinson’s. Samples of sebum were taken from their upper backs for analysis. Using different mass spectrometry methods, 10 chemical compounds in sebum were identified which are elevated or reduced in people with Parkinson’s. This allows scientists to distinguish people with Parkinson’s with 85% accuracy.

The team confirmed their earlier findings published in ACS Central Science that the volatile compounds on skin can be used to diagnose the condition, increasing the number of people sampled and including participants from the Netherlands, as well as the UK.

In a new study published today in Nature Communications, high resolution mass spectrometry was used to profile the complex chemical signature in sebum of people with Parkinson’s and show subtle but fundamental changes as the condition progresses. Detailed analysis showed changes in people with Parkinson’s in lipid (fat) processing and mitochondria. Problems with mitochondria, the tiny energy-producing batteries that power cells, are 1 of the hallmarks of Parkinson’s.

This means this ‘world first’ testing strategy is not only useful in diagnosing Parkinson’s, but also in monitoring the development of the condition. The skin swab could provide an incredibly important new tool in clinical trials helping researchers measure whether new, experimental treatments are able to slow, stop or reverse the progression of Parkinson’s.

The study unveiled novel diagnostic sebum-based biomarkers for Parkinson’s, provides insight into understanding of how the condition develops, and links lipid dysregulation to altered mitochondrial function.

These promising results published today could lead to a definitive test to diagnose Parkinson’s accurately, speedily and cost effectively. The team is now seeking funding to further develop the test and explore the potential for using the test to ‘stratify’ patients. 

Working with the University of Manchester Innovation Factory, the team has patents filed for their diagnostic techniques and are planning to create a spin-out company to commercialise the new tests. They're also working to use this approach to develop tests for COVID-19 as shown in research last week in EClinical Medicine as well as other conditions and are actively seeking investors interested in supporting the drive to bring this technology to market. 

Professor Perdita Barran, Professor of Mass Spectrometry at The University of Manchester, said:

“We believe that our results are an extremely encouraging step towards tests that could be used to help diagnose and monitor Parkinson’s. 

“Not only is the test quick, simple and painless but it should also be extremely cost-effective because it uses existing technology that is already widely available.

“We are now looking to take our findings forwards to refine the test to improve accuracy even further and to take steps towards making this a test that can be used in the NHS and to develop more precise diagnostics and better treatment for this debilitating condition.”

Parkinson’s tends to develop gradually and it may be many months, even years, before the symptoms become obvious enough for an individual to visit their GP. A DaTscan is regularly used to help specialists confirm the loss of dopamine-producing cells that cause the development of Parkinson’s. However, similar loss may also occur in some other rarer neurological conditions.

With no molecular test for the condition, diagnosis is made by a neurologist based on a combination of symptoms such as tremor, slowness, stiffness and balance issues. However, many of the symptoms of Parkinson’s can overlap with other conditions, especially in the early stages when progression is gradual and symptoms are more subtle.

In a recent survey of more than 2,000 people with Parkinson’s carried out by Parkinson’s UK, more than a quarter (26%) reported they were misdiagnosed with a different condition before receiving the correct Parkinson’s diagnosis.¹

Professor David Dexter, Associate Director of Research at Parkinson’s UK, said:

“We are proud to have part-funded this groundbreaking research which marks a significant step towards developing a quick and accurate test that can not only revolutionise the way we diagnose Parkinson’s, but also allow us to monitor how this debilitating condition progresses. 

“Every hour, two more people in the UK are diagnosed with Parkinson’s and a significant portion of these people may well have been misdiagnosed with, and treated for, another condition before receiving their correct diagnosis. This has been compounded in the COVID-19 pandemic where people have been left waiting and have faced months of anxiety to confirm their diagnosis by a health professional. However, with this innovative test, we could see people being diagnosed quickly and accurately enabling them to access vital treatment and support to manage their Parkinson’s symptoms sooner.”

56 year old Daxa Kalayci lives in Leicester and was diagnosed with Parkinson’s in September 2019. She was misdiagnosed several times over four years before finally finding out she had the condition:

“I was misdiagnosed with anxiety, stress-related tremors and told that my problems stemmed from going through the menopause. I embarked on a 4 month cruise across the globe not knowing I had Parkinson’s. Just two weeks into the trip, my symptoms worsened and my dream holiday turned into a nightmare. Without confirmation that it was Parkinson’s, which I had suspected for a long time, I was left with unpleasant side-effects caused by different medications prescribed to manage my symptoms.

“Despite my diagnosis eventually being confirmed by a DaTscan, a quick and simple diagnostic test for Parkinson’s would have given me the chance to start my treatment earlier and enjoy life a lot more. But instead, I lost so many years not being able to pursue a career as a paramedic or go back to Nursing.

“This test could be a game-changer for people living with Parkinson’s and searching for answers like I was. I am so happy with this news because it will mean that in future people won’t have to experience the anxiety of multiple appointments, long waiting times and sleepless nights. The sooner this test is available, the better. Anything that can help people looking for a diagnosis is a bonus.”

ENDS

For more information and interviews, please contact:

Ben Robinson
News and Media Relations Officer
The University of Manchester
[email protected] / 0792 0750 602

Anita Salhotra, Senior Media and PR Officer at Parkinson’s UK on 020 7932 1361  / 07812 737 697 or [email protected] 

Out of hours please call 07961 460 248 or email [email protected]

Notes for editors:

This press release highlights the findings reported in two papers:

“Validating differential volatilome profiles in Parkinson’s disease” Eleanor Sinclair, Caitlin Walton-Doyle, Depanjan Sarkar, Katherine Hollywood, Joy Milne, Sze Lim, Tilo Kunath, Anouk Rijs, Rob DeBie, Monty Silverdale, Drupad Trivedi, Perdita Barran (2021) - published in ACS Central Science, DOI: 10.1021/acscentsci.0c01028 

In this article the authors have shown that people with Parkinson’s have a particular set of volatile compounds. By taking skin swabs from people and measuring the compounds that emanate from these with mass spectrometry, they can diagnose Parkinson’s with 85% accuracy.

“Metabolomics of sebum reveals lipid dysregulation in Parkinson’s disease” Eleanor Sinclair, Drupad Trivedi, Depanjan Sarkar, Caitlin Walton-Doyle, Joy Milne, Tilo Kunath, Anouk Rijs, Rob Debie, Royston Goodacre, Monty Silverdale, Perdita Barran (2021) - published in Nature Communications. DOI: 10.1038/s41467-021-21669-4

The authors have developed a highly novel sebum analysis that uses mass spectrometry for early Parkinson’s diagnosis. Their findings show that the progression of the disease occurs with changes in the regulation of lipids in cells. Of particular interest they can see evidence for changes in the mitochondria of people with Parkinson’s disease - all from non-invasive sampling from sebum on the skin surface.

¹About the misdiagnosis survey carried out by Parkinson’s UK -  In 2019, more than 2,000 people with Parkinson’s were asked about whether they had been misdiagnosed with another condition before getting their Parkinson’s diagnosis, and the impact this had on them. The survey was carried out by Opinium and can be read about here

The key findings were as follows:

The poll of more than 2,000 people, found 26% were first told they had something else. As a result, almost half of this group (48%) were given treatment for their non-existent condition, with 36% receiving medication and 6% undergoing operations or procedures.

Of those receiving unnecessary treatment, more than a third (34%) reported that their health got worse as a result

More than a fifth of people (21%) saw their GP 3 or more times before being referred to a specialist.

The poll also found that women were more likely to be misdiagnosed than men, and errors were most common in people aged 51 to 60.

The partners

This new research includes collaborations with Vrije Universiteit Amsterdam, The University of Edinburgh, and Liverpool University.

About The University of Manchester

The University of Manchester is a member of the prestigious Russell Group and one of the UK’s largest single-site universities. 

We have over 40,000 students, 12,000 staff and, with almost 480,000 former students from more than 190 countries, are home to the largest alumni community of any campus-based university in the UK. No fewer than 25 Nobel laureates have either worked or studied here. 

We are the top UK University for graduate employability according to The Times and Sunday Times Good University Guide; ranked 27th in the world in the QS World University Rankings (2020) and 6th in the UK. We’re also listed as 8th in Reuters Top 100: Europe's most innovative universities (2019).

Visit www.manchester.ac.uk for further information or https://www.manchester.ac.uk/discover/vision/ for our latest strategic vision.

About Parkinson’s and Parkinson’s UK
 
Parkinson’s is what happens when the brain cells that make dopamine start to die. There are more than 40 symptoms, from tremor and pain to anxiety. Some are treatable, but the drugs can have serious side effects. It gets worse over time and there’s no cure. Yet.

Parkinson’s is the fastest growing neurological condition in the world. Around 145,000 people in the UK have Parkinson’s.

For more facts and statistics, please click here.

Further information, advice and support is available on our website, www.parkinsons.org.uk.